New insights in the “personalized” therapy of NSCL cancer Paolo Marchetti Oncologia Medica Azienda Ospedaliera Sant’Andrea & IDI IRCCS Roma Highlights.

Slides:



Advertisements
Similar presentations
1Kitasato-Harvard Symposium 10/03/2002 New Monoclonal Antibody Approved for Advanced Breast Cancer Shin-ichi Nihira, Ph.D. Dept. Clinical Research 3 Chugai.
Advertisements

Advances and Emerging Therapy for Lung Cancer
Highligths in management of gastrointestinal cancer April 11, 2008 CONTROVERSIES IN THE CONTROVERSIES IN THE ADJUVANT THERAPY ADJUVANT THERAPY OF GASTRIC.
James R. Rigas Comprehensive Thoracic Oncology Program
Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice.
Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD.
Treatment in Advanced Non-Small Cell Lung Cancer.
Non-small Cell Lung Cancer
Paz-Ares LG et al. Proc ASCO 2011;Abstract CRA7510.
Questions and answers about PARAMOUNT: phase III study of pemetrexed continuation maintenance therapy in advanced non-squamous NSCLC.
A trial for women with –‘Triple negative’ breast cancer (TNBC) –Localised to breast +/- lymph nodes –Recommended standard treatment involves NEPTUNE Taxane.
Carolina Breast Cancer Study: Breast cancer subtypes and race Robert Millikan University of North Carolina Chapel Hill, NC.
Randomized Trial of p53 Targeted Adjuvant Therapy for Patients (pts) With Organ-Confined Node-Negative Urothelial Bladder Cancer.
Staging. Treatment by Stage For early stage lung cancers, surgery or radiation alone For larger tumors (>4 cm) and N+, chemotherapy should be added.
A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Inhibitor Gefitinb in Completely Resected Stage.
Departments - Surgery - Gerontology and Geriatrics Department of SurgeryDepartment of Gerontology & Geriatrics Prof. dr. C.J.H. van de VeldeProf. dr. R.G.J.
Non-Small-Cell Lung Cancer Leading cause of cancer-related mortality in the US Current Therapies: –“ Despite great efforts, only minor gains” Traynor.
KRAS is mutated in about 40% of colorectal cancers; it is the only validated predictive marker used in patients with metastatic CRC 1. It is also a negative.
Predictors of HER2 FISH amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis Maria Vittoria Dieci 1,
Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.
Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway are Associated with Clinical Outcomes in Esophageal Cancer Patients Treated with Chemoradiotherapy.
First-Line TKI Use in EGFR Mutation-Positive NSCLC
EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.
Margaret Tempero, M.D. Professor of Medicine University of California, San Francisco Debate: This house believes that FOLFIRINOX is the best treatment.
LUNG CANCER: ASCO 2006 TOPICS Adjuvant therapy Clinical studies Meta-analysis ChemoXRT for stage III disease Advances in stage IV NSCLC New agents Predictive.
Optimal use of adjuvant chemotherapy for patients with stage I, II, or IIIA disease Francesco Grossi Oncologia Medica A Disease Management Team - Lung.
Stem Cells In Clinical Practice: STELLA Experience Manolo D’Arcangelo Department of Oncology Ospedale Civile di Livorno.
ERCC 1 isoform expression and DNA repair in NSCLC
Kathleen D. Danenberg Response Genetics, Inc. Predictive and Prognostic Markers for Gastric Cancer.
LUNG ADENOCARCINOMAS. CLINICOPATHOLOGICAL STUDY WITH RESPECT TO THE UPCOMING NEW CLASSIFICATION AND EGFR-KRAS MUTATION ANALYSIS IMPLICATIONS. First author:
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.
Ovarian Clear Cell Carcinomas - from the eyes of biological markers Speaker: Cheng MH Modulator: Twu NF Date: Jan 15, 2007.
Prognose mittels Genexpression Prof. Martin H. Brutsche Kantonsspital St. Gallen-CH.
INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,
Treatment for metastatic bladdercancer (chemotherapy&radiotherapy) Dr.Mina Tajvidi oncologist.
Gene Expression Signatures for Prognosis in NSCLC, Coupled with Signatures of Oncogenic Pathway Deregulation, Provide a Novel Approach for Selection of.
Prognostic and Predictive Factors: Current Evidence for Individualized Therapy Predictive Molecular Markers: Hormone Receptor Status Presented by Kathleen.
A paradigm shift in the treatment of advanced lung cancer: survival and symptom benefits with Tarceva Tudor-Eliade Ciuleanu Cancer Institute Ion Chiricuta.
Overall survival in NSCLC
Introduction Patients and Methods Results Conclusion Table 1. Baseline characteristics of the 108 patients included in the biomarker analysis. Objectives.
New Proposals for Lung Cancer Staging Akif Turna, MD, PhD, FETCS Yedikule Teaching Hospital for Chest Diseases and Thoracic Surgery, Istanbul, Turkey.
Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)
Personalized medicine in lung cancer R4 김승민. Personalized Medicine in Lung Cancer patients with specific types and stages of cancer should be treated.
Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.
Annals of Oncology 23: 298–304, 2012 종양혈액내과 R4 김태영 / prof. 김시영.
Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer in the Elderly: A Population-Based Study in Ontario, Canada JOURNAL OF CLINICAL ONCOLOGY, VOLUME 30.
Non-small cell lung cancer Lancet 2011;378: Peter Goldstraw, David Ball, James R Jett, Thierry Le Chevalier, Eric Lim, Andrew G Nicholson, Frances.
Lung cancer Gene Kukuy, MD Cardiothoracic Surgery.
R2 김재민 / Prof. 정재헌 Journal conference 1.
Ο ρόλος των μη χειρουργικών θεραπειών στο μη μεταστατικό μυοδιηθητικό καρκίνο ουροδόχου κύστεως Γεώργιος Δ. Λύπας Παθολόγος Ογκολόγος Α’ Ογκολογική Κλινική.
Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in.
Recent Advances in NSCLC Treatment
Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)
MCW Regional Cancer Therapy Program
Intervista a Federico Cappuzzo
Prognosis of younger patients in non-small cell lung cancer
بنام خداوند جان و خرد.
Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer  Ana Belén Custodio, MD, José Luis González-Larriba,
Patient Case 1 Patient Case 1: PET/CT Scan.
Transcriptional Signature of Histone Deacetylases in Breast cancer
Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer  Howard West, MD, Rogerio Lilenbaum, MD, David Harpole,
Chapter 3 Treatment guidelines for NSCLC that does not have targetable driver mutations.
Abstracts Journal of Thoracic Oncology
Overall survival in the IFCT trial comparing a single agent therapy arm (vinorelbine or gemcitabine) and the doublet carboplatin plus weekly paclitaxel.
Practical Guidance on the Management of Pan-Negative NSCLC
Sesion de Controversias nº 5 Conclusiones Carlos Camps
Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer  Ana Belén Custodio, MD, José Luis González-Larriba,
Treated with Neoadjuvant Therapy
Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.
Presentation transcript:

New insights in the “personalized” therapy of NSCL cancer Paolo Marchetti Oncologia Medica Azienda Ospedaliera Sant’Andrea & IDI IRCCS Roma Highlights in the Management of NSCL cancer June 13-14, 2008

Drug sensitivity The Clinical Problem Protein and/or mRNA levels of several genes are beginning to emerge as predictive markers of chemotherapeutic efficacy in NSCLC. Clinical benefit from approved drugs occurs in minority of patients Prediction of response not currently possible for most patients and drugs Goal: –Selection of most effective treatment –Development of new agents MJ Kelley, ASCO 2008

Drug sensitivity The Clinical Problem Lung cancer guidelines recommend drug options as equivalent –Locally advanced NSCLC Cisplatin, carboplatin (--), paclitaxel, docetaxel, vinorelbine, RT + CT –Untreated advanced NSCLC Cisplatin, carboplatin (--), paclitaxel, docetaxel, vinorelbine, gemcitabine, (pemetrexed), or non-platinum doublets –Previously treted NSCLC Docetaxel, pemetrexed, erlotinib MJ Kelley, ASCO 2008

Drug sensitivity: The Clinical Problem Factors Used to Individualize Cancer Treatment Patient factors –Age, sex, race –Performance status –Germline genetics (SNPs, CNV, mutation) –Co-morbility Tumor factors –Size & stage –Histopathology –Biochemical functions (PET scan) –Microenvironment (hypoxia, angiogenesis) –Protein expression (IHC, proteomics) –DNA alterations (mutation, methylation, telomere length) –RNA expression –Metabolites MJ Kelley, ASCO 2008

Drug sensitivity: The Clinical Problem Factors Used to Individualize Cancer Treatment MJ Kelley, ASCO 2008

Targeted Therapy Assumes we know the target Assumes we know how to measure the target Assumes we have an agent that blocks or interferes with the target Assumes the agent is selective and specific for the target

What types of clinical trials should we design? Prognostic vs. predictive factors.

Jean-Charles Soria, ASCO 2008

G.M. Clark, ASCO 2008

Drug sensitivity: The Clinical Problem Factors Used to Individualize Cancer Treatment MJ Kelley, ASCO 2008

Drug sensitivity: The Clinical Problem Factors Used to Individualize Cancer Treatment MJ Kelley, ASCO 2008

Genes Predictive of Chemotherapeutic Efficacy in NSCLC ERCC1, the 5’-endonuclease of the nucleotide excision repair complex, is a molecular determinant for efficacy of platinum-based regimens. RRM1, the regulatory subunit of ribonucleotide reductase, is the molecular target of gemcitabine, and its expression levels are the key determinant of the efficacy of gemcitabine-based regimens. TS, the gatekeeper enzyme of thymidine production, has seemingly emerged as a determinant of efficacy for not only 5-FU but also for pemetrexed. BRCA1, the gene important for DNA damage response, appears to increase efficacy of antimicrotubulin agents such as taxanes while simultaneously mediating resistance to DNAdamaging agents such as platinum.

P.D. – 106 A RT-qPCR-BASED THREE-GENE PROGNOSTIC CLASSIFIER FOR STAGE I NON-SMALL-CELL LUNG CANCER Geneva – Friday, 25 April 2008 Guido Natoli, Stefania Scarpino, Annukka Pasanen, Enrico Duranti, Cecilia Pompili, Ida Paris, Erino Rendina, Luigi Ruco, Paolo Marchetti (University ‘La Sapienza’ – Rome, Italy)

A RT-qPCR-based three-gene prognostic classifier for Stage I NSCLC Despite surgery, patients with pathologic stage I disease have nearly 65% five-year survival after surgery alone and most patients relapse at distant sites. However, the role of adjuvant therapy remains controversial. Consequently, the recognition of indicators capable of identifying patients with stage I NSCLC at higher risk for developing recurrent disease may help clinicians to select adjuvant treatments.

A RT-qPCR-based three-gene prognostic classifier for Stage I NSCLC With this aim, we evaluated the significance of three genes –ERCC1, excision repair cross-complementation group 1; –LCK, lymphocyte-specific protein tyrosin kinase; –DUSP6 dual-specifity phosphatase 6 26 stage I completely resected NSCLC patients using reverse transcription (RT) quantitative polymerase chain reaction (qPCR) from fresh-frozen specimens. Then, we evaluated the association between the level of expression and relapse-free survival (RFS) and a risk index was created.

Low RiskHigh RiskpTest Age (mean ± sd)65 ± 1266 ± t test Gender Fisher’s exact Male10 (83%)13 (93%)0.58 Female2 (17%)1 (7%) Stage Fisher’s exact IA8 (66%)5 (36%)0.24 IB4 (34%)9 (64%) Cell type Chi squared Adenocarcinoma8 (68%)9 (64%) 0.95 Squamous cell2 (16%)3 (18%) Uncertain2 (16%)2 (18%)

Low Risk Group High Risk Group Logrank 2p = Kaplan–Meier estimates of relapse-free survival of 26 patients with stage I NSCLC according to the three-gene signatures (Ercc1, Lck and Dusp-6) as measured by RT-PCR (HR = 3.8; 95% CI = )

ERCC-1 specific immunohisto- chemical staining with the use of the 8F1 antibody Spearman’s correlation between RT-PCR and Immuno- staining to detect ERCC-1 expression: 0.49 (p = 0.01)

LCK immunohistochemical staining (polyclonal antibody) dye tumor-infiltrate instead of tumor-cells

MJ Kelley, ASCO 2008